{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:51:26Z","timestamp":1792673486834,"version":"4.5.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/nm.4015","type":"journal-article","created":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T14:11:17Z","timestamp":1452089477000},"page":"26-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":333,"title":["Prospects for gene-engineered T cell immunotherapy for solid cancers"],"prefix":"10.1038","volume":"22","author":[{"given":"Christopher A","family":"Klebanoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P","family":"Restifo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,6]]},"reference":[{"key":"BFnm4015_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R.J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558\u2013562 (2014).","journal-title":"Nature"},{"key":"BFnm4015_CR6","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015\u20134022 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnm4015_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S.M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR8","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D.T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR9","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","volume":"31","author":"N van Rooij","year":"2013","unstructured":"van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439\u2013e442 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnm4015_CR10","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N.A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"BFnm4015_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P.C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"BFnm4015_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S.A. & Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"key":"BFnm4015_CR14","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S.A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnm4015_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nm.3773","volume":"21","author":"C Linnemann","year":"2015","unstructured":"Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81\u201385 (2015).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins, P.F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747\u2013752 (2013).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR17","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","volume":"20","author":"YC Lu","year":"2014","unstructured":"Lu, Y.C. et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 20, 3401\u20133410 (2014).","journal-title":"Clin. Cancer Res."},{"key":"BFnm4015_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"BFnm4015_CR19","doi-asserted-by":"publisher","unstructured":"Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science http:\/\/dx.doi.org\/10.1126\/science.aad1253 (2015).","DOI":"10.1126\/science.aad1253"},{"key":"BFnm4015_CR20","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","volume":"194","author":"F Djenidi","year":"2015","unstructured":"Djenidi, F. et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475\u20133486 (2015).","journal-title":"J. Immunol."},{"key":"BFnm4015_CR21","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovi\u0107","year":"2015","unstructured":"Stevanovi\u0107, S. et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 33, 1543\u20131550 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnm4015_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/imr.12137","volume":"257","author":"H Singh","year":"2014","unstructured":"Singh, H., Huls, H., Kebriaei, P. & Cooper, L.J. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol. Rev. 257, 181\u2013190 (2014).","journal-title":"Immunol. Rev."},{"key":"BFnm4015_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P.W. et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR24","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132\u20133142 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnm4015_CR25","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra53 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5\u201329 (2015).","journal-title":"CA Cancer J. Clin."},{"key":"BFnm4015_CR27","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/blood-2011-04-346338","volume":"118","author":"M Ahmadi","year":"2011","unstructured":"Ahmadi, M. et al. CD3 limits the efficacy of TCR gene therapy in vivo. Blood 118, 3528\u20133537 (2011).","journal-title":"Blood"},{"key":"BFnm4015_CR28","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1182\/blood-2013-04-495531","volume":"122","author":"D Abate-Daga","year":"2013","unstructured":"Abate-Daga, D. et al. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood 122, 1399\u20131410 (2013).","journal-title":"Blood"},{"key":"BFnm4015_CR29","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1084\/jem.20150304","volume":"212","author":"DC Palmer","year":"2015","unstructured":"Palmer, D.C. et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J. Exp. Med. 212, 2095\u20132113 (2015).","journal-title":"J. Exp. Med."},{"key":"BFnm4015_CR30","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720\u2013724 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4015_CR31","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HT Khong","year":"2002","unstructured":"Khong, H.T. & Restifo, N.P. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat. Immunol. 3, 999\u20131005 (2002).","journal-title":"Nat. Immunol."},{"key":"BFnm4015_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A.H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","volume":"3","author":"MJ Frigault","year":"2015","unstructured":"Frigault, M.J. et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 3, 356\u2013367 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"BFnm4015_CR34","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John, L.B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636\u20135646 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnm4015_CR35","unstructured":"Recombinant DNA Advisory Committee Meeting Workshop on Cytokine Release Syndrome after T Cell Immunotherapy. June 10th, 2015. https:\/\/auth.osp.od.nih.gov\/sites\/default\/files\/resources\/RAC_Agenda_Day2%28CRS%29_UPDATED.pdf . 6\u201315\u20132015."},{"key":"BFnm4015_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P.F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"BFnm4015_CR37","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","volume":"100","author":"OL Caballero","year":"2009","unstructured":"Caballero, O.L. & Chen, Y.T. Cancer\/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100, 2014\u20132021 (2009).","journal-title":"Cancer Sci."},{"key":"BFnm4015_CR38","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D.L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR39","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J.N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"BFnm4015_CR40","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer, J.N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709\u20132720 (2012).","journal-title":"Blood"},{"key":"BFnm4015_CR41","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer, J.N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540\u2013549 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnm4015_CR42","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens, R.J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817\u20134828 (2011).","journal-title":"Blood"},{"key":"BFnm4015_CR43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR44","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R.J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR45","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S.A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR46","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D.W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"BFnm4015_CR47","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR48","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M.L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR49","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall, A.L. et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373, 1040\u20131047 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR50","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D.W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"BFnm4015_CR51","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw, M.H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106\u20136115 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnm4015_CR52","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers, C.H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20\u2013e22 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnm4015_CR53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.iy.07.040189.002405","volume":"7","author":"WJ Rettig","year":"1989","unstructured":"Rettig, W.J. & Old, L.J. Immunogenetics of human cell surface differentiation. Annu. Rev. Immunol. 7, 481\u2013511 (1989).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnm4015_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495\u2013497 (1975).","journal-title":"Nature"},{"issue":"2 Pt A","key":"BFnm4015_CR55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","volume":"67","author":"JM Redman","year":"2015","unstructured":"Redman, J.M., Hill, E.M., AlDeghaither, D. & Weiner, L.M. Mechanisms of action of therapeutic antibodies for cancer. Mol. Immunol. 67, 2 Pt A, 28\u201345 (2015).","journal-title":"Mol. Immunol."},{"key":"BFnm4015_CR56","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","volume":"125","author":"P Stashenko","year":"1980","unstructured":"Stashenko, P., Nadler, L.M., Hardy, R. & Schlossman, S.F. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125, 1678\u20131685 (1980).","journal-title":"J. Immunol."},{"key":"BFnm4015_CR57","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.4049\/jimmunol.151.5.2380","volume":"151","author":"TM Ellis","year":"1993","unstructured":"Ellis, T.M., Simms, P.E., Slivnick, D.J., J\u00e4ck, H.M. & Fisher, R.I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J. Immunol. 151, 2380\u20132389 (1993).","journal-title":"J. Immunol."},{"key":"BFnm4015_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood.V62.1.124.124","volume":"62","author":"RG Andrews","year":"1983","unstructured":"Andrews, R.G., Torok-Storb, B. & Bernstein, I.D. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 62, 124\u2013132 (1983).","journal-title":"Blood"},{"key":"BFnm4015_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","volume":"15","author":"F Malavasi","year":"1994","unstructured":"Malavasi, F. et al. Human CD38: a glycoprotein in search of a function. Immunol. Today 15, 95\u201397 (1994).","journal-title":"Immunol. Today"},{"key":"BFnm4015_CR60","doi-asserted-by":"publisher","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","volume":"7","author":"SP Rao","year":"2012","unstructured":"Rao, S.P. et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 7, e39416 (2012).","journal-title":"PLoS One"},{"key":"BFnm4015_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/376337a0","volume":"376","author":"PJ Miettinen","year":"1995","unstructured":"Miettinen, P.J. et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337\u2013341 (1995).","journal-title":"Nature"},{"key":"BFnm4015_CR62","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone, S.A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459\u2013465 (2002).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR63","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu, A.L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324\u20131334 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR64","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106, 3360\u20133365 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4015_CR65","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli, P.S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR66","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","volume":"74","author":"I Pastan","year":"2014","unstructured":"Pastan, I. & Hassan, R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 74, 2907\u20132912 (2014).","journal-title":"Cancer Res."},{"key":"BFnm4015_CR67","doi-asserted-by":"publisher","unstructured":"Tanyi, J.L. et al. Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers. Proceedings of AACR Annual Meeting 2015. Cancer Res. http:\/\/dx.doi.org\/10.1158\/1538-7445.AM2015-CT105 (2015).","DOI":"10.1158\/1538-7445.AM2015-CT105"},{"key":"BFnm4015_CR68","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru, M., O'Cearbhaill, R., Pendharkar, S., Spriggs, D.R. & Brentjens, R.J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015).","journal-title":"J. Transl. Med."},{"key":"BFnm4015_CR69","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1096\/fj.14-257352","volume":"28","author":"D Haridas","year":"2014","unstructured":"Haridas, D. et al. MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J. 28, 4183\u20134199 (2014).","journal-title":"FASEB J."},{"key":"BFnm4015_CR70","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R.A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"BFnm4015_CR71","first-page":"953","volume":"5","author":"MF Press","year":"1990","unstructured":"Press, M.F., Cordon-Cardo, C. & Slamon, D.J. Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953\u2013962 (1990).","journal-title":"Oncogene"},{"key":"BFnm4015_CR72","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688\u20131696 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnm4015_CR73","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis, C.U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050\u20136056 (2011).","journal-title":"Blood"},{"key":"BFnm4015_CR74","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nbt.2725","volume":"31","author":"CS Hinrichs","year":"2013","unstructured":"Hinrichs, C.S. & Restifo, N.P. Reassessing target antigens for adoptive T-cell therapy. Nat. Biotechnol. 31, 999\u20131008 (2013).","journal-title":"Nat. Biotechnol."},{"key":"BFnm4015_CR75","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L.A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"BFnm4015_CR76","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M.R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).","journal-title":"Mol. Ther."},{"key":"BFnm4015_CR77","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1126\/science.aab4082","volume":"349","author":"I Martincorena","year":"2015","unstructured":"Martincorena, I. & Campbell, P.J. Somatic mutation in cancer and normal cells. Science 349, 1483\u20131489 (2015).","journal-title":"Science"},{"key":"BFnm4015_CR78","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1073\/pnas.89.7.2965","volume":"89","author":"AJ Wong","year":"1992","unstructured":"Wong, A.J. et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 89, 2965\u20132969 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4015_CR79","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1089\/hum.2012.041","volume":"23","author":"RA Morgan","year":"2012","unstructured":"Morgan, R.A. et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23, 1043\u20131053 (2012).","journal-title":"Hum. Gene Ther."},{"key":"BFnm4015_CR80","doi-asserted-by":"publisher","first-page":"275ra22","DOI":"10.1126\/scitranslmed.aaa4963","volume":"7","author":"LA Johnson","year":"2015","unstructured":"Johnson, L.A. et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra22 (2015).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR81","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","volume":"21","author":"LM Draper","year":"2015","unstructured":"Draper, L.M. et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin. Cancer Res. 21, 4431\u20134439 (2015).","journal-title":"Clin. Cancer Res."},{"key":"BFnm4015_CR82","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2011.116","volume":"8","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S.A. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat. Rev. Clin. Oncol. 8, 577\u2013585 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnm4015_CR83","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ijc.1282","volume":"92","author":"AA Jungbluth","year":"2001","unstructured":"Jungbluth, A.A. et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J. Cancer 92, 856\u2013860 (2001).","journal-title":"Int. J. Cancer"},{"key":"BFnm4015_CR84","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1073\/pnas.93.12.5915","volume":"93","author":"YT Chen","year":"1996","unstructured":"Chen, Y.T. et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. Natl. Acad. Sci. USA 93, 5915\u20135919 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4015_CR85","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder, N.N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698\u20132703 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR86","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan, R.A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133\u2013151 (2013).","journal-title":"J. Immunother."},{"key":"BFnm4015_CR87","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","volume":"21","author":"AP Rapoport","year":"2015","unstructured":"Rapoport, A.P. et al. NY-ESO-1\u2013specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914\u2013921 (2015).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR88","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda, H. et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6, 199\u2013208 (1997).","journal-title":"Immunity"},{"key":"BFnm4015_CR89","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4049\/jimmunol.1001775","volume":"186","author":"N Chinnasamy","year":"2011","unstructured":"Chinnasamy, N. et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186, 685\u2013696 (2011).","journal-title":"J. Immunol."},{"key":"BFnm4015_CR90","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G.P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"BFnm4015_CR91","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron, B.J. et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR92","doi-asserted-by":"publisher","first-page":"D913","DOI":"10.1093\/nar\/gkq1128","volume":"39","author":"FF Gonzalez-Galarza","year":"2011","unstructured":"Gonzalez-Galarza, F.F., Christmas, S., Middleton, D. & Jones, A.R. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39, D913\u2013D919 (2011).","journal-title":"Nucleic Acids Res."},{"key":"BFnm4015_CR93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2010.00979.x","volume":"239","author":"CA Klebanoff","year":"2011","unstructured":"Klebanoff, C.A., Acquavella, N., Yu, Z. & Restifo, N.P. Therapeutic cancer vaccines: are we there yet? Immunol. Rev. 239, 27\u201344 (2011).","journal-title":"Immunol. Rev."},{"key":"BFnm4015_CR94","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T.N. & Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"BFnm4015_CR95","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-11-2614","volume":"72","author":"RS Andersen","year":"2012","unstructured":"Andersen, R.S. et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642\u20131650 (2012).","journal-title":"Cancer Res."},{"key":"BFnm4015_CR96","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E.M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"BFnm4015_CR97","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nbt.2892","volume":"32","author":"JG Lohr","year":"2014","unstructured":"Lohr, J.G. et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat. Biotechnol. 32, 479\u2013484 (2014).","journal-title":"Nat. Biotechnol."},{"key":"BFnm4015_CR98","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12065","volume":"497","author":"M Murtaza","year":"2013","unstructured":"Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108\u2013112 (2013).","journal-title":"Nature"},{"key":"BFnm4015_CR99","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros, A. et al. PD-1 identifies the patient-specific CD8 tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246\u20132259 (2014).","journal-title":"J. Clin. Invest."},{"key":"BFnm4015_CR100","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/nm.3359","volume":"19","author":"C Linnemann","year":"2013","unstructured":"Linnemann, C. et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat. Med. 19, 1534\u20131541 (2013).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR101","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44\u201355 (2014).","journal-title":"Clin. Cancer Res."},{"key":"BFnm4015_CR102","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1172\/JCI82416","volume":"125","author":"CJ Cohen","year":"2015","unstructured":"Cohen, C.J. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125, 3981\u20133991 (2015).","journal-title":"J. Clin. Invest."},{"key":"BFnm4015_CR103","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/nprot.2006.121","volume":"1","author":"B Rodenko","year":"2006","unstructured":"Rodenko, B. et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat. Protoc. 1, 1120\u20131132 (2006).","journal-title":"Nat. Protoc."},{"key":"BFnm4015_CR104","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc3322","volume":"12","author":"L Gattinoni","year":"2012","unstructured":"Gattinoni, L., Klebanoff, C.A. & Restifo, N.P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671\u2013684 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4015_CR105","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.it.2014.02.003","volume":"35","author":"JG Crompton","year":"2014","unstructured":"Crompton, J.G., Clever, D., Vizcardo, R., Rao, M. & Restifo, N.P. Reprogramming antitumor immunity. Trends Immunol. 35, 178\u2013185 (2014).","journal-title":"Trends Immunol."},{"key":"BFnm4015_CR106","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","volume":"12","author":"R Vizcardo","year":"2013","unstructured":"Vizcardo, R. et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells. Cell Stem Cell 12, 31\u201336 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFnm4015_CR107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","volume":"12","author":"T Nishimura","year":"2013","unstructured":"Nishimura, T. et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12, 114\u2013126 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFnm4015_CR108","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature10135","volume":"474","author":"T Zhao","year":"2011","unstructured":"Zhao, T., Zhang, Z.N., Rong, Z. & Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature 474, 212\u2013215 (2011).","journal-title":"Nature"},{"key":"BFnm4015_CR109","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature11807","volume":"494","author":"R Araki","year":"2013","unstructured":"Araki, R. et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494, 100\u2013104 (2013).","journal-title":"Nature"},{"key":"BFnm4015_CR110","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.stem.2013.01.006","volume":"12","author":"P Guha","year":"2013","unstructured":"Guha, P., Morgan, J.W., Mostoslavsky, G., Rodrigues, N.P. & Boyd, A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12, 407\u2013412 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFnm4015_CR111","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cell.2010.10.008","volume":"143","author":"JH Hanna","year":"2010","unstructured":"Hanna, J.H., Saha, K. & Jaenisch, R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 143, 508\u2013525 (2010).","journal-title":"Cell"},{"key":"BFnm4015_CR112","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli, M. et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928\u2013933 (2013).","journal-title":"Nat. Biotechnol."},{"key":"BFnm4015_CR113","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm.3267","volume":"19","author":"AS Lee","year":"2013","unstructured":"Lee, A.S., Tang, C., Rao, M.S., Weissman, I.L. & Wu, J.C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998\u20131004 (2013).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR114","first-page":"128ra42","volume":"4","author":"GC Wang","year":"2012","unstructured":"Wang, G.C., Dash, P., McCullers, J.A., Doherty, P.C. & Thomas, P.G. T cell receptor \u03b1\u03b2 diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci. Transl. Med. 4, 128ra42 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR115","doi-asserted-by":"publisher","first-page":"301ra131","DOI":"10.1126\/scitranslmed.aac5624","volume":"7","author":"B Howie","year":"2015","unstructured":"Howie, B. et al. High-throughput pairing of T cell receptor \u03b1 and \u03b2 sequences. Sci. Transl. Med. 7, 301ra131 (2015).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR116","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/hum.2010.064","volume":"22","author":"SA Feldman","year":"2011","unstructured":"Feldman, S.A. et al. Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a 'modified' step-filtration process for clearance of packaging cells. Hum. Gene Ther. 22, 107\u2013115 (2011).","journal-title":"Hum. Gene Ther."},{"key":"BFnm4015_CR117","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/mt.2011.288","volume":"20","author":"AS Bear","year":"2012","unstructured":"Bear, A.S. et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol. Ther. 20, 246\u2013249 (2012).","journal-title":"Mol. Ther."},{"key":"BFnm4015_CR118","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","volume":"68","author":"H Singh","year":"2008","unstructured":"Singh, H. et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 68, 2961\u20132971 (2008).","journal-title":"Cancer Res."},{"key":"BFnm4015_CR119","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox, D.B., Platt, R.J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121\u2013131 (2015).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR120","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/bit.25538","volume":"112","author":"N Kacherovsky","year":"2015","unstructured":"Kacherovsky, N., Liu, G.W., Jensen, M.C. & Pun, S.H. Multiplexed gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selection. Biotechnol. Bioeng. 112, 1429\u20131436 (2015).","journal-title":"Biotechnol. Bioeng."},{"key":"BFnm4015_CR121","doi-asserted-by":"publisher","first-page":"e68201","DOI":"10.1371\/journal.pone.0068201","volume":"8","author":"AC Field","year":"2013","unstructured":"Field, A.C. et al. Comparison of lentiviral and sleeping beauty mediated \u03b1\u03b2 T cell receptor gene transfer. PLoS One 8, e68201 (2013).","journal-title":"PLoS One"},{"key":"BFnm4015_CR122","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/CJI.0000000000000032","volume":"37","author":"D Rushworth","year":"2014","unstructured":"Rushworth, D. et al. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J. Immunother. 37, 204\u2013213 (2014).","journal-title":"J. Immunother."},{"key":"BFnm4015_CR123","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/CJI.0b013e31827806e6","volume":"35","author":"CA Klebanoff","year":"2012","unstructured":"Klebanoff, C.A., Gattinoni, L. & Restifo, N.P. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J. Immunother. 35, 651\u2013660 (2012).","journal-title":"J. Immunother."},{"key":"BFnm4015_CR124","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-11-0503","volume":"17","author":"CA Klebanoff","year":"2011","unstructured":"Klebanoff, C.A. et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343\u20135352 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnm4015_CR125","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00262-013-1459-x","volume":"62","author":"A Casati","year":"2013","unstructured":"Casati, A. et al. Clinical-scale selection and viral transduction of human na\u00efve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol. Immunother. 62, 1563\u20131573 (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnm4015_CR126","doi-asserted-by":"publisher","first-page":"e35798","DOI":"10.1371\/journal.pone.0035798","volume":"7","author":"C Stemberger","year":"2012","unstructured":"Stemberger, C. et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting. PLoS One 7, e35798 (2012).","journal-title":"PLoS One"},{"key":"BFnm4015_CR127","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR128","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114\u20131117 (2010).","journal-title":"Nature"},{"key":"BFnm4015_CR129","doi-asserted-by":"crossref","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. (2015).","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"BFnm4015_CR130","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nm999","volume":"10","author":"MT Spiotto","year":"2004","unstructured":"Spiotto, M.T., Rowley, D.A. & Schreiber, H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10, 294\u2013298 (2004).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR131","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/JCI34388","volume":"118","author":"B Breart","year":"2008","unstructured":"Breart, B., Lema\u00eetre, F., Celli, S. & Bousso, P. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J. Clin. Invest. 118, 1390\u20131397 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnm4015_CR132","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","volume":"121","author":"SP Kerkar","year":"2011","unstructured":"Kerkar, S.P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746\u20134757 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnm4015_CR133","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard, C.M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol. 32, 798\u2013808 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnm4015_CR134","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/0008-5472.CAN-10-2693","volume":"71","author":"V Corbi\u00e8re","year":"2011","unstructured":"Corbi\u00e8re, V. et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71, 1253\u20131262 (2011).","journal-title":"Cancer Res."},{"key":"BFnm4015_CR135","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","volume":"276","author":"C Bonini","year":"1997","unstructured":"Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719\u20131724 (1997).","journal-title":"Science"},{"key":"BFnm4015_CR136","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nm0296-216","volume":"2","author":"SR Riddell","year":"1996","unstructured":"Riddell, S.R. et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2, 216\u2013223 (1996).","journal-title":"Nat. Med."},{"key":"BFnm4015_CR137","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof, K.C. et al. An inducible caspase-9 safety switch for T-cell therapy. Blood 105, 4247\u20134254 (2005).","journal-title":"Blood"},{"key":"BFnm4015_CR138","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4015_CR139","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","volume":"123","author":"X Zhou","year":"2014","unstructured":"Zhou, X. et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase-9 safety transgene. Blood 123, 3895\u20133905 (2014).","journal-title":"Blood"},{"key":"BFnm4015_CR140","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263 (2011).","journal-title":"Blood"},{"key":"BFnm4015_CR141","doi-asserted-by":"publisher","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao, Y. et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70, 9053\u20139061 (2010).","journal-title":"Cancer Res."},{"key":"BFnm4015_CR142","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71\u201375 (2013).","journal-title":"Nat. Biotechnol."},{"key":"BFnm4015_CR143","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V.D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR144","doi-asserted-by":"publisher","first-page":"207ra144","DOI":"10.1126\/scitranslmed.3006682","volume":"5","author":"LR Desnoyers","year":"2013","unstructured":"Desnoyers, L.R. et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci. Transl. Med. 5, 207ra144 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4015_CR145","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu, C.Y., Roybal, K.T., Puchner, E.M., Onuffer, J. & Lim, W.A. Remote control of therapeutic T cells through a small-molecule-gated chimeric receptor. Science 350, aab4077 (2015).","journal-title":"Science"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.4015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4015","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T07:42:53Z","timestamp":1692171773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.4015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFnm4015"],"URL":"https:\/\/doi.org\/10.1038\/nm.4015","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.R. reports receiving research support in the form of Cooperative Research and Development Agreements (CRADAs) with KITE Pharma, Lion Biotechnologies and Intrexon; C.A.K. and N.P.R. report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}